GlassScriptPhysician profile
Sonia M Benn
NPI 1801825781
$25,686.54
in general payments reported to CMS, 2019-2025
57 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $366 · 2021: $762 · 2022: $1,011 · 2023: $1,257 · 2024: $6,327 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $5,231 · Consulting Fee: $2,450 · Long Term Medical Supply Or Device Loan: $2,082 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,295.00 |
| Food and Beverage | $5,231.42 |
| Consulting Fee | $2,450.00 |
| Long Term Medical Supply Or Device Loan | $2,081.77 |
| Education | $177.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,557.02 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $5,450.99 | 2021-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $2,281.21 | 2019-2025 | |
| Gilead Sciences, INC. | $877.38 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $844.00 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $383.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $346.35 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $318.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $298.49 | 2021-2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $290.61 | 2019-2025 | Jaypirca, Verzenio |
| Abbvie INC. | $283.47 | 2019-2025 | Venclexta |
| Amgen INC. | $251.77 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.51 | 2020-2025 | Ninlaro |
| Eisai INC. | $208.44 | 2019-2025 | |
| Celgene Corporation | $191.57 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Benn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.